MDM2/MDMX inhibitor peptide: WO2008106507

Bibliography

• Meulmeester E, Jochemsen AG. p53: a guide to apoptosis. Curr Cancer Drug Targets 2008;8(2):87-97
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6(12):909-23
   PubMed Web of Science ®Google Scholar
• Barboza JA, Iwakuma T, Terzian T, et al. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 2008;6(6):947-54
   PubMed Web of Science ®Google Scholar
• Marine JC, Francoz S, Maetens M, et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006;13(6):927-34
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8(4):275-83
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007;39(7-8):1476-82
   PubMed Web of Science ®Google Scholar
• Halatsch ME, Schmidt U, Unterberg A, Vougioukas VI. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res 2006;26(6B):4191-4
   Google Scholar
• Laurie NA, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets 2007;7(7):689-95
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444(7115):61-6
   PubMed Web of Science ®Google Scholar
• Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 2008;17(12):1865-82
   PubMed Web of Science ®Google Scholar
• Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13(1):23-31
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• Hu B, Gilkes DM, Farooqi B, et al. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281(44):33030-5
   PubMed Web of Science ®Google Scholar
• Gilkes DM, Chen J. Distinct roles of MDMX in the regulation of p53 response to ribosomal stress. Cell Cycle 2007;6(2):151-5
   PubMed Web of Science ®Google Scholar
• Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007;120(Pt 3):371-8
   PubMed Web of Science ®Google Scholar
• Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007;67(18):8810-7
   PubMed Web of Science ®Google Scholar
• Bottger A, Bottger V, Sparks A, et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997;7(11):860-9
   PubMed Web of Science ®Google Scholar
• Bottger V, Bottger A, Howard SF, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996;13(10):2141-7
   PubMed Web of Science ®Google Scholar
• Bottger A, Bottger V, Garcia-Echeverria C, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997;269(5):744-56
   PubMed Web of Science ®Google Scholar
• Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274(5289):948-53
   PubMed Web of Science ®Google Scholar
• Popowicz GM, Czarna A, Rothweiler U, et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007;6(19):2386-92
   PubMed Web of Science ®Google Scholar
• Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008;7(15):2441-3
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Hoogland C, Gattiker A, et al. Protein Identification and Analysis Tools on the ExPASy Server. In: WJ, M. editor, The proteomics protocols handbook: Humana Press 2005. p. 571-607
   Google Scholar
• Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157(1):105-32
   PubMed Web of Science ®Google Scholar
• Bhaskaran R, Ponnuswammy PK. Positional flexibilities of amino acid residues in globular proteins. Int J Pept Protein Res 1988;32:242-55
   Google Scholar
• Zimmerman JM, Eliezer N, Simha R. The characterization of amino acid sequences in proteins by statistical methods. J Theor Biol 1968;21:170-201
   PubMed Web of Science ®Google Scholar
• Macchiarulo A, Pellicciari R. Exploring the other side of biologically relevant chemical space: insights into carboxylic, sulfonic and phosphonic acid bioisosteric relationships. J Mol Graph Model 2007;26(4):728-39
   Google Scholar
• Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr Opin Mol Ther 2008;10(5):439-48
   PubMedGoogle Scholar
• Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450(7172):1001-9
   PubMed Web of Science ®Google Scholar
• Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci 2004;25(7):343-6
   PubMedGoogle Scholar
• Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3(4):301-17
   PubMed Web of Science ®Google Scholar
• Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel 2008;11(5):666-74
   PubMedGoogle Scholar
• Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008;14(21):2100-10
   PubMed Web of Science ®Google Scholar
• Corallini F, Celeghini C. The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL). J Leukoc Biol 2008;84(3):651
   Google Scholar
• Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008;105(10):3933-8
   PubMed Web of Science ®Google Scholar